GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » ROE %

Myovant Sciences (Myovant Sciences) ROE % : 0.00% (As of Dec. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Myovant Sciences's annualized net income for the quarter that ended in Dec. 2022 was $-230.5 Mil. Myovant Sciences's average Total Stockholders Equity over the quarter that ended in Dec. 2022 was $-535.7 Mil. Therefore, Myovant Sciences's annualized ROE % for the quarter that ended in Dec. 2022 was N/A%.

The historical rank and industry rank for Myovant Sciences's ROE % or its related term are showing as below:

MYOV's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.085
* Ranked among companies with meaningful ROE % only.

Myovant Sciences ROE % Historical Data

The historical data trend for Myovant Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences ROE % Chart

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
ROE %
Get a 7-Day Free Trial -140.10 -1,300.67 - - -

Myovant Sciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Myovant Sciences's ROE %

For the Biotechnology subindustry, Myovant Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myovant Sciences's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's ROE % falls into.



Myovant Sciences ROE % Calculation

Myovant Sciences's annualized ROE % for the fiscal year that ended in Mar. 2022 is calculated as

ROE %=Net Income (A: Mar. 2022 )/( (Total Stockholders Equity (A: Mar. 2021 )+Total Stockholders Equity (A: Mar. 2022 ))/ count )
=-205.981/( (-353.965+-473.477)/ 2 )
=-205.981/-413.721
=N/A %

Myovant Sciences's annualized ROE % for the quarter that ended in Dec. 2022 is calculated as

ROE %=Net Income (Q: Dec. 2022 )/( (Total Stockholders Equity (Q: Sep. 2022 )+Total Stockholders Equity (Q: Dec. 2022 ))/ count )
=-230.508/( (-513.249+-558.143)/ 2 )
=-230.508/-535.696
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2022) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Myovant Sciences  (NYSE:MYOV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2022 )
=Net Income/Total Stockholders Equity
=-230.508/-535.696
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-230.508 / 400.916)*(400.916 / 443.7475)*(443.7475 / -535.696)
=Net Margin %*Asset Turnover*Equity Multiplier
=-57.5 %*0.9035*N/A
=ROA %*Equity Multiplier
=-51.95 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2022 )
=Net Income/Total Stockholders Equity
=-230.508/-535.696
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-230.508 / -225.688) * (-225.688 / -207.58) * (-207.58 / 400.916) * (400.916 / 443.7475) * (443.7475 / -535.696)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0214 * 1.0872 * -51.78 % * 0.9035 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2022) net income data. The Revenue data used here is four times the quarterly (Dec. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Myovant Sciences ROE % Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences (Myovant Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek director, officer: Principal Executive Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona officer: Chief Medical Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra officer: Principal Financial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka director 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran director C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe officer: Principal Fin'l & Accounting C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo director ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957

Myovant Sciences (Myovant Sciences) Headlines

From GuruFocus